Drugs / AZ-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04327765 | Mar → Aug 2020 | — | Alexza Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZ-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04327765 ↗ |
| Known as | Staccato Granisetron | “A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers” NCT04327765 ↗ |
| Route | Inhaled | “single inhaled dose” NCT04327765 ↗ |